Dr. Steven Nissen and AstraZeneca will take whatever actions they can to
denigrate Vascepa whenever or however they can. Epanova, in my opinion,
is a nonstarter regardless of results simply because of the diarrhea side
effect. Besides, AMRN will most likely use their legal firepower to keep
Epanova off the market. Once it is obvious to AZN that Epanova cannot
compete, what might they decide to do? AZN has a market cap of around
$125 billion, just under that of AMGN with $130 billion. The Omega-3
prescription market in Europe is up for grabs. Like Game of Thrones,
who will sit on the throne? Europe will have 11 years free of generic
competition. If an acquirer emerges for AMRN the European market may
be the main inducement. That fact must be obvious to AZN. Would AZN
sit back and watch if Pfizer, Roche, Novartis, Lilly, Merck, or Novo
Nordisk were to launch a bid? Keep in mind many of these names are
now selling around 52 week highs. In all honesty I just cannot see
AMRN being allowed to GIA when there are so many large and hungry
sharks prowling around.
News 
Market Data 
Discover 
AI
